Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Authors
Keywords
Epidermal growth factor receptor, Drug resistance, Epigenetics, Gefitinib, MET proto-oncogene
Journal
CANCER LETTERS
Volume 495, Issue -, Pages 41-52
Publisher
Elsevier BV
Online
2020-09-10
DOI
10.1016/j.canlet.2020.09.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p
- (2020) Yu Sun et al. JOURNAL OF HEPATOLOGY
- Targeting mitosis exit: A brake for cancer cell proliferation
- (2019) Xinran Liu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer
- (2019) Sofia Genta et al. Current Oncology Reports
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
- (2019) Qiming Wang et al. Journal of Hematology & Oncology
- Histone methyltransferase G9a protects against acute liver injury through GSTP1
- (2019) Yu Zhang et al. CELL DEATH AND DIFFERENTIATION
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
- (2018) Lixin Wan et al. MOLECULAR CELL
- Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma
- (2018) Xinran Liu et al. Cell Death & Disease
- Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
- (2018) Yuchen Chen et al. Computational and Structural Biotechnology Journal
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- Histone demethylase UTX is a therapeutic target for diabetic kidney disease
- (2018) Hong Chen et al. JOURNAL OF PHYSIOLOGY-LONDON
- Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase
- (2017) Shanshan Liu et al. HEPATOLOGY
- ELABELA and an ELABELA Fragment Protect against AKI
- (2017) Hong Chen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- METCopy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis ofEGFR-mutant Lung Cancer
- (2017) Shigeki Nanjo et al. MOLECULAR CANCER THERAPEUTICS
- MacroH2A1.1 cooperates with EZH2 to promote adipogenesis by regulating Wnt signaling
- (2017) Danyang Wan et al. Journal of Molecular Cell Biology
- ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ
- (2017) Yu Zhang et al. Nature Communications
- EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics
- (2017) Itaru Yamamoto et al. Oncotarget
- Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance
- (2017) Heinz Hammerlindl et al. Journal of Cell Communication and Signaling
- Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
- (2016) Li Zhang et al. CHINESE MEDICAL JOURNAL
- Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
- (2016) Stefanie Göllner et al. NATURE MEDICINE
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer
- (2015) Muyang Ding et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression
- (2015) Nienke A. de Vries et al. Cell Reports
- Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
- (2014) Claudia Fumarola et al. BIOCHEMICAL PHARMACOLOGY
- MPHOSPH1: A Potential Therapeutic Target for Hepatocellular Carcinoma
- (2014) X. Liu et al. CANCER RESEARCH
- VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy
- (2014) E. Riquelme et al. CLINICAL CANCER RESEARCH
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- (2013) Yuankai Shi et al. LANCET ONCOLOGY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny
- (2012) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- MYC Acts via the PTEN Tumor Suppressor to Elicit Autoregulation and Genome-Wide Gene Repression by Activation of the Ezh2 Methyltransferase
- (2012) M. Kaur et al. CANCER RESEARCH
- Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B
- (2012) Xiang Li et al. CARCINOGENESIS
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells
- (2009) S. Benavente et al. CLINICAL CANCER RESEARCH
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now